EP3292134B1 - Method of culturing akkermansia - Google Patents
Method of culturing akkermansia Download PDFInfo
- Publication number
- EP3292134B1 EP3292134B1 EP16722128.2A EP16722128A EP3292134B1 EP 3292134 B1 EP3292134 B1 EP 3292134B1 EP 16722128 A EP16722128 A EP 16722128A EP 3292134 B1 EP3292134 B1 EP 3292134B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- muciniphila
- growth
- amino acid
- glucose
- akkermansia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention is in the field of culturing bacteria, in particular bacteria of the genus Akkermansia, particularly of the species Akkermansia muciniphila.
- Bacteria of the genus Akkermansia are thought to play an important role in the prevention and/or treatment of metabolic disorders, such as, for example, obesity related disorders ( WO2014/075745 ; WO2014/077246 ). It was found that oral administration of A. muciniphila to mice fed a control diet or a high-fat (HF) diet normalized diet-induced metabolic endotoxemia, adiposity and adipose tissue CD11c marker without any changes in food intake ( WO2014/075745 ). Moreover, A. muciniphila treatment reduced body weight and improved body composition (i.e., fat/lean mass ratio).
- HF high-fat
- A. muciniphila treatment increased mRNA expression of markers of adipocyte differentiation and lipid oxidation without affecting lipogenesis. It was also found that colonization with A. muciniphila completely reversed diet-induced fasting hyperglycemia, and the insulin-resistance index was similarly reduced after treatment. Finally, it has been found that A. muciniphila increases the intestinal barrier function ( J Reunanen et al. 2015, Appl Environ Microbiol. 81:3655-62 ). As such, it has been suggested to use bacteria of the genus Akkermansia, particularly of the species A. muciniphila, in food or pharmaceutical applications. As such, high biomass yields of Akkermansia are desired.
- A. muciniphila strain MucT can be isolated and grown on a basal anaerobic medium containing hog gastric mucin as the sole carbon and nitrogen source.
- the authors also teach that A. muciniphila can be grown on rich media, such as Columbia Broth (CB) and Brain Heart Infusion (BHI) broth, but with a final optical density that is half the final optical density that can be obtained with the mucin medium. All media suitable for culturing Akkermansia known so far contain animal components.
- BHI derives from animal tissue, and CB contains enzymatic digests of bovine casein, animal tissue and heart muscle.
- A. muciniphila is not easily cultured, as is illustrated by the observation that no growth was observed on the rich Wilkens-Chalgren Broth (WCB) (Derrien et al., 2004).
- WCB is specifically designed to grow anaerobic bacteria and contains among others enzymatic digests of bovine casein and animal gelatin.
- A. muciniphila has been described to be incapable of growth on basal salt medium with one of the following compounds (each 10 mM unless stated otherwise) glucose, cellobiose, lactose, galactose, xylose, fucose, rhamnose, maltose, succinate, acetate, fumarate, butyrate, lactate, casitone (0.5%), casamino acids (0.5%), tryptone (0.5%), peptone (0.5%), yeast extract (0.5%), proline, glycine, aspartate, serine, threonine, glutamate, alanine, N-acetylglucosamine, N-acetylgalactosamine (Derrien et al., 2004).
- A. muciniphila was grown in basal medium with 10 g/l casitone (equals 1%), 5 mM glucose and 5 mM fucose and 1 mM threonine ( Lukovac et al., 2014, MBio. 12;5(4). pii: e01438-14. (doi: 10.1128/mBio.01438-14 )). Also here the growth yield was low and approximately 4 x lower than that obtained when A. muciniphila is grown on mucus-containing medium. Moreover, the medium contained a high concentration of casitone, which is a proteolytic degradation product of the bovine milk protein casein, and therefore is of animal origin. Finally, the medium did not only contain the cheap sugar glucose but also the sugar fucose, which is mainly found in animal derived products and is over 100 time more expensive than glucose.
- A. muciniphila cannot easily be cultured, and that all media and growth conditions described so far include the use of animal-derived compounds.
- Animal-derived products could contain contaminants of viral, prion or bacterial origin, or contain allergens, antigenic peptides or other undesired products, or may otherwise be considered unsuitable for culturing Akkermansia for food or pharmaceutical application in humans, for example, because they are of a non-kosher or non-halal origin.
- mucus-containing media have been found to yield the greatest amount of biomass. As mucus is only found in animals, this is a limitation to grow A.
- Such culture medium would allow large scale production of Akkermansia suitable for use in humans, e.g., for food, feed or pharmaceutical applications.
- the present invention provides for a method of culturing bacteria of the genus Akkermansia, particularly of the species Akkermansia muciniphila, said method comprising the steps of: providing a composition comprising a monosaccharide, a nitrogen-containing derivative of a monosaccharide, and an amino acid source; inoculating said composition with bacteria of the genus Akkermansia; and allowing said bacteria of the genus Akkermansia to multiply.
- the nitrogen-containing derivative of a monosaccharide is selected from N-acetyl-glucosamine (Glc-NAc) and N-acetyl-galactosamine (Gal-Nac). It is preferably Glc-NAc.
- the Glc-NAc may be present in an amount ranging from about 0.001 mM to about 1 M, such as from about 0.1 mM to about 500 mM, from about 0.5 mM to about 100 mM, from about 1 mM to about 75 mM, or from about 5 mM to about 50 mM.
- the monosaccharide is glucose.
- the glucose may be present in an amount ranging from about 0.001 M to about 1 M, such as from about 0.1 mM to about 500 mM, from about 0.5 mM to about 100 mM, from about 1 mM to about 75 mM, or from about 5 mM to about 50 mM.
- composition may further comprise threonine, for example in an amount ranging from about 0.01 mM to about 100 mM.
- the amino acid source in the composition may be selected from a plant-based amino acid source, a microbial-based amino acid source, or a combination of alanine, glutamate, proline and serine.
- the amino acid source is a plant protein hydrolysate, such as a soy protein hydrolysate, a pea protein hydrolysate, a wheat protein hyrolysate, a rice protein hydrolysate, a cotton protein hydrolysate, and the like.
- the plant protein hydrolysate may be present in an amount ranging from about 0.01 g/l to about 1 kg/I, such as from about 0.05 to about 500 g/l, from about 0.1 to about 250 g/l, from about 0.5 to about 150 g/l, from about 1 to about 100 g/l, or from about 2 to about 80 g/l.
- Akkermansia muciniphila could be cultured to very high optical density in a composition comprising glucose, N-acetyl-glucosamine, and an amino acid source.
- the amino acid source may ideally be fully plant or microbial based.
- the present disclosure also relates to a composition for culturing bacteria, particularly of the genus Akkermansia, specifically Akkermansia muciniphila, comprising a monosaccharide, a nitrogen-containing derivative of a monosaccharide, and an amino acid source.
- the monosaccharide may be any monosaccharide, particularly one that is commonly used for cost-effectively culturing bacteria, and is preferably glucose.
- the nitrogen-containing derivative of a monosaccharide may be selected from N-acetyl-glucosamine (Glc-NAc) and N-acetyl-galactosamine (Gal-Nac), and is preferably N-acetyl-glucosamine.
- the composition may comprise the monosaccharide, such as glucose, in a concentration ranging from about 0.001 mM to about 1 M, such as from about 0.1 mM to about 500 mM, from about 0.5 mM to about 100 mM, from about 1 mM to about 75 mM, or from about 5 mM to about 50 mM.
- the monosaccharide such as glucose
- the composition may comprise the nitrogen-containing derivative of a monosaccharide, such as Glc-NAc, in a concentration ranging from about 0.001 mM to about 1 M, such as from about 0.1 mM to about 500 mM, from about 0.5 mM to about 100 mM, from about 1 mM to about 75 mM, or from about 5 mM to about 50 mM.
- a monosaccharide such as Glc-NAc
- composition of this disclosure may be free of animal derived products.
- the amino acid source may be any amino acid source known to the skilled person, and includes, without limitation, an amino acid source derived from an animal, derived form a plant, or derived from a microorganism.
- the amino acid source may be, for instance, a protein hydrolysate, such as plant-derived protein hydrolysates.
- Protein hydrolysates are manufactured from protein sources using (partial) hydrolysis and are typically composed of a mixture of peptides, amino acids, carbohydrates and lipids, and a multitude of unidentified components with indeterminate biological activity. They are often produced by the enzymatic, alkaline or acidic digestion of a given raw material from various sources, such as, without limitation, plant sources, e.g., soy, wheat, pea, chickpea or cotton.
- the amino acid source may include commercial amino acid sources such as: yeast extracts, for example, the ultrafiltered HyPepTM YE or UltraPepTM YE, or Hy-YestTM; dairy hydrolysates, for example, derived from casein, lactalbumin and milk solid hydrolysates, such as AmicaseTM, Hy-CaseTM Amino, Hy-CaseTM SF, N-Z-AmineTM A, N-Z-AmineTM AS, N-Z-AmineTM EKC, N-Z-CaseTM Plus, N-Z-CaseTM TT, Edamin F, or Tryptone (the assortment of peptides formed by the digestion of casein by the protease trypsin); Plant protein hydrolysates such as HyPep 1510TM (enzymatic hydrolysate of soy), HyPep 1511TM (ultrafiltered enzymatic digest of soy), HyPep 1512TM (enzymatic digest of soy), HyP
- the amino acid source may be comprised in the composition of the invention in an amount ranging from about 0.01 g/l to about 1 kg/I, such as from about 0.05 to about 500 g/l, from about 0.1 to about 250 g/l, from about 0.5 to about 150 g/l, from about 1 to about 100 g/l, or from about 2 to about 80 g/l.
- HySoy or Amisoy may be incorporated in the composition taught herein in an amount ranging from about 0.01 g/l to about 1 kg/I, such as from about 0.05 to about 500 g/l, from about 0.1 to about 250 g/l, from about 0.5 to about 150 g/l, from about 1 to about 100 g/l, or from about 2 to about 80 g/l.
- the composition of the invention comprises threonine, such as in an amount of about 0.01 to about 100 mM, preferably about 0.05 to about 50 mM, even more preferably about 0.1 to about 25 mM, yet more preferably about 0.5 to about 15 mM, more preferably about 1 to about 10 mM, such as about 1 to about 8 mM.
- the threonine may be present in the form of L-threonine or D,L-threonine.
- composition of the invention may comprise alanine, glutamate, proline and serine, preferably each in an amount of about 0.01 to about 100 mM, preferably about 0.05 to about 50 mM, even more preferably about 0.1 to about 25 mM, yet more preferably about 0.5 to about 15 mM, more preferably about 1 to about 10 mM, such as about 1 to about 8 mM.
- the composition as taught herein further comprises a buffer system to maintain the pH in the range of 5.5-8.0, preferably of 6.0-7.0, more preferably around pH 6.6.
- a buffer system to maintain the pH in the range of 5.5-8.0, preferably of 6.0-7.0, more preferably around pH 6.6.
- the skilled person is capable of selecting a buffer system suitable for this purpose.
- composition as taught herein further comprises from about 0.1 to about 2%, such as from about 0.3 to about 1.5%, or from about 0.5 to about 1.3%, or around about 1.0% cysteine.
- vitamins may be added to the composition taught herein. Suitable vitamins that may be included, encompass, without limitation, biotin, cobalamin, PABA, folic acid, pyridoxamine, and the like.
- cobalamin can be employed when propionate is required as metabolic end-product instead of succinate, via the cobalamin-dependent methyl malonyl CoA mutase.
- the present invention also provides a method for culturing bacteria of the genus Akkermansia, particularly of the species Akkermansia municiphila, said method comprising the steps of:
- Suitable culturing conditions for Akkermansia muciniphila include, without limitation, a temperature in the range of 20-40 °C and a pH in the range of 5.5-8.0, with optimum growth at a temperature of about 36-38 °C and pH 6.0-7.0, preferably around pH 6.5.
- Akkermansia muciniphila is a strictly anaerobic bacterium ( Derrien et al. 2004. Int J System Evol Microbiol 54:1469-1476 ), and as such anaerobic conditions should ideally be applied to the extent possible, and contact with air should be avoided to the extent possible. The skilled person is acquainted with anaerobic culturing methods.
- Example 1 Growth of A. muciniphila is stimulated by glucose and N-acetylglucosamine
- A.muciniphila Muc T (ATTC BAA-835) was grown in basal anaerobic medium as described previously (Derrien et al., 2004, supra ).
- the medium was supplemented with purified hog mucus alone (Type III; Sigma; 0.5 %), with mucus (0.25 %) alone or with added sugars, or with tryptone (Difco; 1 %) with added sugars.
- the used sugars included D-glucose (Glucose), D-fucose (Fucose), or N-acetylglucosamine (GlcNac), alone at 20 mM or in combination at 10 mM final concentration, respectively.
- Incubations with sugars also contained 1 mM D,L threonine (Threonine). All incubations were carried out in serum bottles sealed with butyl-rubber stoppers at 37 °C under anaerobic conditions provided by a gas phase of 182 kPa (1.8 atm) N2/CO2. Growth was determined spectrophotometrically as optical density at 600 nm (OD600) and the results are shown in Table A. In addition, HPLC analysis was used as described previously (Derrien et al., 2004, supra; Luzovac et al., 2014, supra ) to determine the concentration of the indicated sugars as well as the products, including acetate, propionate, 1,2-propanediol. Table A. Growth of A.
- muciniphila on various substrates.
- the compounds added to the basal medium are indicated with their concentrations (dimensions in between brackets) as is the OD600, which is determined after 24-60 h of incubation. Entries are from repeated experiments and varied up to approximately 25 % between experiments. For abbreviations see text. The different sets of experiments are spaced for clarity.
- N-acetylglucosamine would be the best sugar to sustain growth of A.muciniphila; however, in view of the scarcity and costs of this sugar, it would be more advantageous to use glucose. It was surprisingly found that by combining glucose with N-acetylglucosamine, the growth of A. muciniphila was much better than on glucose only (Table A).
- Example 2 Growth of A. muciniphila is stimulated by threonine
- Example 3 Growth of A. muciniphila in non-animal derived and synthetic media
- casein is an animal-derived protein source, it was tested whether plant-based or microbe-based protein sources could be used to support growth of A. muciniphila. Since soy is one of the most abundant and complete protein sources, a number of commercial hydrolyzed soy preparations were tested. Good growth of A.muciniphila was observed on basal media with glucose and N-acetylglucosamine with HySoy and AmiSoy, both obtained from Quest International, previously found to sustain growth of pathogenic bacteria (see US patent 6558926 and WO 1998054296 ). However, in all cases the addition of threonine supported growth as is shown in Table C. Highly efficient growth of A. muciniphila was obtained with 2 mM and even better growth with 4 mM threonine in the presence of 16 g/l HySoy.
- yeast extract (Difco) was added. Yeast extracts are usually more expensive than soy based media ( Kwon et al., Enzyme Microb Technol. 2000 Feb 1;26(2-4):209-215 .) and hence a relatively small amount of yeast extract was added to the medium that supported growth of A. muciniphila to OD600 of 4.4 and it was found to even increase growth of A. muciniphila to OD600 6.5 (Table C). This indicates that yeast extract can be used to support growth and also indicates that increasing the protein source can further increase growth of A.muciniphila on non-animal derived media.
- Example 4 Industrial scale fermentation of A.muciniphila
- A.muciniphila was grown on a basal medium as described above containing per kg 32 gram HySoy, 25 gram glucose, 4.4 gram N-acetylglucosamine, 4 gram threonine, 0.5 gram cysteine, and a vitamin solution (see Derrient et al 2004, vide supra ) in a 600 liter fermentor at pH 7.0. After the fermentation the OD600 of the culture was 7.2, indicating that the medium with the glucose, N-acetyl-glucosamine and a non-animal protein source was capable of sustaining excellent growth of A.muciniphila at an industrial scale level.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
- The present invention is in the field of culturing bacteria, in particular bacteria of the genus Akkermansia, particularly of the species Akkermansia muciniphila.
- Bacteria of the genus Akkermansia, particularly of the species Akkermansia muciniphila, are thought to play an important role in the prevention and/or treatment of metabolic disorders, such as, for example, obesity related disorders (
WO2014/075745 ;WO2014/077246 ). It was found that oral administration of A. muciniphila to mice fed a control diet or a high-fat (HF) diet normalized diet-induced metabolic endotoxemia, adiposity and adipose tissue CD11c marker without any changes in food intake (WO2014/075745 ). Moreover, A. muciniphila treatment reduced body weight and improved body composition (i.e., fat/lean mass ratio). It was found that under HF-diet, A. muciniphila treatment increased mRNA expression of markers of adipocyte differentiation and lipid oxidation without affecting lipogenesis. It was also found that colonization with A. muciniphila completely reversed diet-induced fasting hyperglycemia, and the insulin-resistance index was similarly reduced after treatment. Finally, it has been found that A. muciniphila increases the intestinal barrier function (J Reunanen et al. 2015, Appl Environ Microbiol. 81:3655-62). As such, it has been suggested to use bacteria of the genus Akkermansia, particularly of the species A. muciniphila, in food or pharmaceutical applications. As such, high biomass yields of Akkermansia are desired. - Derrien et al. (2004, Int. J. Syst. Evol. Microbiol. 54: 1469-76) teach that A. muciniphila strain MucT can be isolated and grown on a basal anaerobic medium containing hog gastric mucin as the sole carbon and nitrogen source. The authors also teach that A. muciniphila can be grown on rich media, such as Columbia Broth (CB) and Brain Heart Infusion (BHI) broth, but with a final optical density that is half the final optical density that can be obtained with the mucin medium. All media suitable for culturing Akkermansia known so far contain animal components. BHI derives from animal tissue, and CB contains enzymatic digests of bovine casein, animal tissue and heart muscle. A. muciniphila is not easily cultured, as is illustrated by the observation that no growth was observed on the rich Wilkens-Chalgren Broth (WCB) (Derrien et al., 2004). WCB is specifically designed to grow anaerobic bacteria and contains among others enzymatic digests of bovine casein and animal gelatin.
- Moreover, A. muciniphila has been described to be incapable of growth on basal salt medium with one of the following compounds (each 10 mM unless stated otherwise) glucose, cellobiose, lactose, galactose, xylose, fucose, rhamnose, maltose, succinate, acetate, fumarate, butyrate, lactate, casitone (0.5%), casamino acids (0.5%), tryptone (0.5%), peptone (0.5%), yeast extract (0.5%), proline, glycine, aspartate, serine, threonine, glutamate, alanine, N-acetylglucosamine, N-acetylgalactosamine (Derrien et al., 2004).
- However, only when 2 g/l (0.2 %) of each peptone, yeast extract, tryptone and casitone was added to the basal medium, either of the sugars N-acetylglucosamine, N-acetylgalactosamine or glucose (10 mM each) supported growth but growth was less than a quarter of that on mucin medium (Derrien et al., 2004).
- In a recent study, published ten years after its original description, A. muciniphila was grown in basal medium with 10 g/l casitone (equals 1%), 5 mM glucose and 5 mM fucose and 1 mM threonine (Lukovac et al., 2014, MBio. 12;5(4). pii: e01438-14. (doi: 10.1128/mBio.01438-14)). Also here the growth yield was low and approximately 4 x lower than that obtained when A. muciniphila is grown on mucus-containing medium. Moreover, the medium contained a high concentration of casitone, which is a proteolytic degradation product of the bovine milk protein casein, and therefore is of animal origin. Finally, the medium did not only contain the cheap sugar glucose but also the sugar fucose, which is mainly found in animal derived products and is over 100 time more expensive than glucose.
- Hence, it is evident that A. muciniphila cannot easily be cultured, and that all media and growth conditions described so far include the use of animal-derived compounds. Animal-derived products could contain contaminants of viral, prion or bacterial origin, or contain allergens, antigenic peptides or other undesired products, or may otherwise be considered unsuitable for culturing Akkermansia for food or pharmaceutical application in humans, for example, because they are of a non-kosher or non-halal origin. Hitherto, mucus-containing media have been found to yield the greatest amount of biomass. As mucus is only found in animals, this is a limitation to grow A. muciniphila and challenges the applications of this bacterium aimed to improve human or animal health as suggested in the present scientific and patent literature. Moreover, no isolates of A. muciniphila other than strain MucT have been described. The growth and isolation of A. muciniphila has been found to be challenging, as has recently been illustrated in a study where only an enrichment was obtained but not a pure culture of A. muciniphila in spite of significant efforts (Caputo et al 2015, Biol Direct 10: 5 (doi:10.1186/s13062-015-0041-1)) indicating that its growth is a major bottleneck.
- It was an aim of the present invention to provide a composition that could be used to culture bacteria of the genus Akkermansia to high final optical density (high biomass yield) and/or that has reduced complexity compared to presently known compositions for culturing bacteria of the genus Akkermansia, and that is preferably free of animal derived products. Such culture medium would allow large scale production of Akkermansia suitable for use in humans, e.g., for food, feed or pharmaceutical applications.
- The present invention provides for a method of culturing bacteria of the genus Akkermansia, particularly of the species Akkermansia muciniphila, said method comprising the steps of: providing a composition comprising a monosaccharide, a nitrogen-containing derivative of a monosaccharide, and an amino acid source; inoculating said composition with bacteria of the genus Akkermansia; and allowing said bacteria of the genus Akkermansia to multiply.
- The nitrogen-containing derivative of a monosaccharide is selected from N-acetyl-glucosamine (Glc-NAc) and N-acetyl-galactosamine (Gal-Nac). It is preferably Glc-NAc. The Glc-NAc may be present in an amount ranging from about 0.001 mM to about 1 M, such as from about 0.1 mM to about 500 mM, from about 0.5 mM to about 100 mM, from about 1 mM to about 75 mM, or from about 5 mM to about 50 mM.
- The monosaccharide is glucose. The glucose may be present in an amount ranging from about 0.001 M to about 1 M, such as from about 0.1 mM to about 500 mM, from about 0.5 mM to about 100 mM, from about 1 mM to about 75 mM, or from about 5 mM to about 50 mM.
- The composition may further comprise threonine, for example in an amount ranging from about 0.01 mM to about 100 mM.
- The amino acid source in the composition may be selected from a plant-based amino acid source, a microbial-based amino acid source, or a combination of alanine, glutamate, proline and serine. In a suitable embodiment, the amino acid source is a plant protein hydrolysate, such as a soy protein hydrolysate, a pea protein hydrolysate, a wheat protein hyrolysate, a rice protein hydrolysate, a cotton protein hydrolysate, and the like.
- The plant protein hydrolysate may be present in an amount ranging from about 0.01 g/l to about 1 kg/I, such as from about 0.05 to about 500 g/l, from about 0.1 to about 250 g/l, from about 0.5 to about 150 g/l, from about 1 to about 100 g/l, or from about 2 to about 80 g/l.
- The present inventors found that Akkermansia muciniphila could be cultured to very high optical density in a composition comprising glucose, N-acetyl-glucosamine, and an amino acid source. The amino acid source may ideally be fully plant or microbial based.
- Thus, the present disclosure also relates to a composition for culturing bacteria, particularly of the genus Akkermansia, specifically Akkermansia muciniphila, comprising a monosaccharide, a nitrogen-containing derivative of a monosaccharide, and an amino acid source.
- The monosaccharide may be any monosaccharide, particularly one that is commonly used for cost-effectively culturing bacteria, and is preferably glucose.
- The nitrogen-containing derivative of a monosaccharide may be selected from N-acetyl-glucosamine (Glc-NAc) and N-acetyl-galactosamine (Gal-Nac), and is preferably N-acetyl-glucosamine.
- The composition may comprise the monosaccharide, such as glucose, in a concentration ranging from about 0.001 mM to about 1 M, such as from about 0.1 mM to about 500 mM, from about 0.5 mM to about 100 mM, from about 1 mM to about 75 mM, or from about 5 mM to about 50 mM.
- The composition may comprise the nitrogen-containing derivative of a monosaccharide, such as Glc-NAc, in a concentration ranging from about 0.001 mM to about 1 M, such as from about 0.1 mM to about 500 mM, from about 0.5 mM to about 100 mM, from about 1 mM to about 75 mM, or from about 5 mM to about 50 mM.
- The composition of this disclosure may be free of animal derived products.
- The amino acid source may be any amino acid source known to the skilled person, and includes, without limitation, an amino acid source derived from an animal, derived form a plant, or derived from a microorganism. The amino acid source may be, for instance, a protein hydrolysate, such as plant-derived protein hydrolysates. Protein hydrolysates are manufactured from protein sources using (partial) hydrolysis and are typically composed of a mixture of peptides, amino acids, carbohydrates and lipids, and a multitude of unidentified components with indeterminate biological activity. They are often produced by the enzymatic, alkaline or acidic digestion of a given raw material from various sources, such as, without limitation, plant sources, e.g., soy, wheat, pea, chickpea or cotton.
- The amino acid source may include commercial amino acid sources such as: yeast extracts, for example, the ultrafiltered HyPep™ YE or UltraPep™ YE, or Hy-Yest™; dairy hydrolysates, for example, derived from casein, lactalbumin and milk solid hydrolysates, such as Amicase™, Hy-Case™ Amino, Hy-Case™ SF, N-Z-Amine™ A, N-Z-Amine™ AS, N-Z-Amine™ EKC, N-Z-Case™ Plus, N-Z-Case™ TT, Edamin F, or Tryptone (the assortment of peptides formed by the digestion of casein by the protease trypsin); Plant protein hydrolysates such as HyPep 1510™ (enzymatic hydrolysate of soy), HyPep 1511™ (ultrafiltered enzymatic digest of soy), HyPep 1512™ (enzymatic digest of soy), HyPep 4601N™ (ultrafiltered enzymatic digest of wheat gluten), HyPep 5603™ (ultrafiltered enzymatic digest of rice protein and wheat gluten), HyPep 7504™ (ultrafiltered enzymatic digest of cotton protein), UltraPep Cotton™, Amisoy (an acid digest of soy isolate, resulting in a mix of amino acids and small peptides but without tryptophan), Phytone or Soytone Peptones (Difco ™ and BBL brand peptones) or UltraPep Soy™. The amino acid source may also be an amino acid composition comprising an individual amino acid or a combination of individual amino acids. In a suitable embodiment, the amino acid source is a plant based amino acid source.
- The amino acid source may be comprised in the composition of the invention in an amount ranging from about 0.01 g/l to about 1 kg/I, such as from about 0.05 to about 500 g/l, from about 0.1 to about 250 g/l, from about 0.5 to about 150 g/l, from about 1 to about 100 g/l, or from about 2 to about 80 g/l. For example, HySoy or Amisoy may be incorporated in the composition taught herein in an amount ranging from about 0.01 g/l to about 1 kg/I, such as from about 0.05 to about 500 g/l, from about 0.1 to about 250 g/l, from about 0.5 to about 150 g/l, from about 1 to about 100 g/l, or from about 2 to about 80 g/l.
- Preferably, the composition of the invention comprises threonine, such as in an amount of about 0.01 to about 100 mM, preferably about 0.05 to about 50 mM, even more preferably about 0.1 to about 25 mM, yet more preferably about 0.5 to about 15 mM, more preferably about 1 to about 10 mM, such as about 1 to about 8 mM. The threonine may be present in the form of L-threonine or D,L-threonine.
- In addition, the composition of the invention may comprise alanine, glutamate, proline and serine, preferably each in an amount of about 0.01 to about 100 mM, preferably about 0.05 to about 50 mM, even more preferably about 0.1 to about 25 mM, yet more preferably about 0.5 to about 15 mM, more preferably about 1 to about 10 mM, such as about 1 to about 8 mM.
- In an embodiment, the composition as taught herein further comprises a buffer system to maintain the pH in the range of 5.5-8.0, preferably of 6.0-7.0, more preferably around pH 6.6. The skilled person is capable of selecting a buffer system suitable for this purpose.
- In an embodiment, the composition as taught herein further comprises from about 0.1 to about 2%, such as from about 0.3 to about 1.5%, or from about 0.5 to about 1.3%, or around about 1.0% cysteine.
- Although not required, vitamins may be added to the composition taught herein. Suitable vitamins that may be included, encompass, without limitation, biotin, cobalamin, PABA, folic acid, pyridoxamine, and the like. For instance, cobalamin can be employed when propionate is required as metabolic end-product instead of succinate, via the cobalamin-dependent methyl malonyl CoA mutase.
- The present invention also provides a method for culturing bacteria of the genus Akkermansia, particularly of the species Akkermansia municiphila, said method comprising the steps of:
- providing a composition as taught herein;
- inoculating said composition with bacteria of the genus Akkermansia;
- allowing said bacteria of the genus Akkermansia to multiply.
- Suitable culturing conditions for Akkermansia muciniphila include, without limitation, a temperature in the range of 20-40 °C and a pH in the range of 5.5-8.0, with optimum growth at a temperature of about 36-38 °C and pH 6.0-7.0, preferably around pH 6.5. Akkermansia muciniphila is a strictly anaerobic bacterium (Derrien et al. 2004. Int J System Evol Microbiol 54:1469-1476), and as such anaerobic conditions should ideally be applied to the extent possible, and contact with air should be avoided to the extent possible. The skilled person is acquainted with anaerobic culturing methods.
- The present invention is further illustrated, but not limited, by the following examples.
- A.muciniphila MucT (ATTC BAA-835) was grown in basal anaerobic medium as described previously (Derrien et al., 2004, supra). The medium was supplemented with purified hog mucus alone (Type III; Sigma; 0.5 %), with mucus (0.25 %) alone or with added sugars, or with tryptone (Difco; 1 %) with added sugars. The used sugars included D-glucose (Glucose), D-fucose (Fucose), or N-acetylglucosamine (GlcNac), alone at 20 mM or in combination at 10 mM final concentration, respectively. Incubations with sugars also contained 1 mM D,L threonine (Threonine). All incubations were carried out in serum bottles sealed with butyl-rubber stoppers at 37 °C under anaerobic conditions provided by a gas phase of 182 kPa (1.8 atm) N2/CO2. Growth was determined spectrophotometrically as optical density at 600 nm (OD600) and the results are shown in Table A. In addition, HPLC analysis was used as described previously (Derrien et al., 2004, supra; Luzovac et al., 2014, supra) to determine the concentration of the indicated sugars as well as the products, including acetate, propionate, 1,2-propanediol.
Table A. Growth of A. muciniphila on various substrates. The compounds added to the basal medium are indicated with their concentrations (dimensions in between brackets) as is the OD600, which is determined after 24-60 h of incubation. Entries are from repeated experiments and varied up to approximately 25 % between experiments. For abbreviations see text. The different sets of experiments are spaced for clarity. Glucose (mM) Fucose (mM) GlcNac (mM) Tryptone (g/l) Mucus (g/l) Growth OD600 - - - - 5 2.5 - - - - 2.5 0.8 - - - - 1.25 0.4 20 - - - 2.5 2.3 - 20 - - 2.5 1.6 - - 20 - 2.5 2.3 20 - - 10 - 0.6 - 20 - 10 - 0.15 - - 20 10 - 1.0 10 10 - 10 - 0.4 10 - 10 10 - 1.0 - The results confirmed earlier observations (Derrien et al., 2004, supra) that 5 g/l mucus sustains good growth of A. muciniphila with a relatively high growth rate (generation time of approximately 2 hours) and high end OD600 of 2.5, representing approximately 5.109 cells per ml. However, reducing the mucus concentration drastically affects the growth of A. muciniphila. Combinations of glucose and other sugars were tested to investigate growth of A. muciniphila. Interestingly, glucose or N-acetylglucosamine, but not so much fucose, can compensate for a two-fold reduction of the mucus concentration to sustain growth of A. muciniphila to OD600 above 2.0. Moreover, from the single sugars notably N-acetylglucosamine and, to a lesser extent, glucose but not fucose could sustain growth of A. muciniphila in the presence of an additional nitrogen source, in this case tryptone, a tryptic digest of casein. Similar results were obtained with casitone, a pancreatic enzyme digest of casein. However, growth was several-fold reduced as compared to growth on basal medium containing 0.5 % mucus, similar to what has been reported previously (Derrien et al., 2004, supra).
- From the described results, one may conclude that N-acetylglucosamine would be the best sugar to sustain growth of A.muciniphila; however, in view of the scarcity and costs of this sugar, it would be more advantageous to use glucose. It was surprisingly found that by combining glucose with N-acetylglucosamine, the growth of A. muciniphila was much better than on glucose only (Table A).
- While for growth of A. muciniphila on glucose, N-acetylglucosamine could be used to increase final optical density, an external protein source was found to be essential to sustain good growth. Remarkably, increasing concentrations of tryptone significantly stimulated the growth of A. muciniphila, up to a level that exceeded the level of growth that could be obtained on mucus-containing media (Table B). An amount of 32 g/l of tryptone was feasible and similar in protein concentration as normal bovine milk.
- The experiment was carried out essentially as set forth in Example 1.
- Additionally, the effect of increasing the concentration of threonine in a basal medium with glucose and N-acetylglucosamine was tested. Surprisingly, a considerable effect was observed with concentrations of threonine above 2 mM and preferably above 4 mM, resulting in a very high OD600 of A. muciniphila above 7.0, which is reaching industrial scale levels.
- Interestingly, both L-threonine and D,L-threonine could be used. As D,L-threonine is more readily available and less costly, addition of D,L-threonine to the medium of the invention is preferred.
Table B. Growth of A. muciniphila on various substrates, optionally including threonine. Glucose (mM) GlcNac (mM) Threonine (mM) Tryptone g/l Growth OD600 12.5 12.5 0 8 0.2 12.5 12.5 0 16 0.5 12.5 12.5 0 32 3.5 25 25 0 32 4.0 25 25 1 32 5.6 25 25 2 32 7.1 25 25 4 32 7.2 - Since casein is an animal-derived protein source, it was tested whether plant-based or microbe-based protein sources could be used to support growth of A. muciniphila. Since soy is one of the most abundant and complete protein sources, a number of commercial hydrolyzed soy preparations were tested. Good growth of A.muciniphila was observed on basal media with glucose and N-acetylglucosamine with HySoy and AmiSoy, both obtained from Quest International, previously found to sustain growth of pathogenic bacteria (see
US patent 6558926 andWO 1998054296 ). However, in all cases the addition of threonine supported growth as is shown in Table C. Highly efficient growth of A. muciniphila was obtained with 2 mM and even better growth with 4 mM threonine in the presence of 16 g/l HySoy. - Changing the ratio of glucose and N-acetylglucosamine in the presence of HySoy and threonine affected the growth of A.muciniphila and showed that also on this soy-based media both sugars are needed but the ratio may differ (Table C). This was also observed on casein-derived tryptone and indicates that optimizing the ratio of glucose and N-acetylglucosamine can be done independently of the nitrogen source.
- To test whether also a microbial protein source could support growth of A. muciniphila yeast extract (Difco) was added. Yeast extracts are usually more expensive than soy based media (Kwon et al., Enzyme Microb Technol. 2000 Feb 1;26(2-4):209-215.) and hence a relatively small amount of yeast extract was added to the medium that supported growth of A. muciniphila to OD600 of 4.4 and it was found to even increase growth of A. muciniphila to OD600 6.5 (Table C). This indicates that yeast extract can be used to support growth and also indicates that increasing the protein source can further increase growth of A.muciniphila on non-animal derived media.
- Evidently, the most cost effective way to grow bacterial cells is on a synthetic medium and hence it was tested what amino acids in the soy hydrolysate could support growth. It was found that a mixture of 4 amino acids, alanine, glutamate, proline and serine (4mM each) could support growth of A. muciniphila without the need for other amino acids apart from threonine in the presence of glucose and N-acetylglucosamine (Table C). The observed growth exceeded the growth on mucus alone (see above) and hence this opens the way for further optimizing the cost-effective growth of A. muciniphila. In fact, serine could also be replaced by threonine and a combination of only threonine and proline was found to be highly effective to act as a nitrogen source for A. muciniphila.
Table C. Growth of A. muciniphila on various substrates and HySoy and yeast extract (YE) at 10 g/l and 4 amino acids (AA), consisting of alanine, glutamate, proline and serine (4 mM each). The experiments were performed essentially as described in Example 5. Glucose (mM) GlcNac (mM) Threonine (mM) HySoy (g/l) Additions Growth OD600 25 25 0 16 - 0.2 25 25 2 16 1.8 25 25 4 16 - 4.4 50 0 2 16 - 0.1 0 50 2 16 - 3.9 40 10 2 16 - 0.3 10 40 2 16 - 2.8 25 25 4 16 YE (10 g/l) 6.5 25 25 4 - AA (4 mM) 2.9 - To illustrate the capacity to produce A.muciniphila at a large scale, it was grown on a basal medium as described above containing per kg 32 gram HySoy, 25 gram glucose, 4.4 gram N-acetylglucosamine, 4 gram threonine, 0.5 gram cysteine, and a vitamin solution (see Derrient et al 2004, vide supra) in a 600 liter fermentor at pH 7.0. After the fermentation the OD600 of the culture was 7.2, indicating that the medium with the glucose, N-acetyl-glucosamine and a non-animal protein source was capable of sustaining excellent growth of A.muciniphila at an industrial scale level.
Claims (10)
- A method of culturing bacteria of the genus Akkermansia, said method comprising the steps of:- Providing a composition comprising glucose, a nitrogen-containing derivative of a monosaccharide selected from N-acetyl-glucosamine (Glc-NAc) and N-acetyl-galactosamine (Gal-NAc), and an amino acid source;- Inoculating said composition with bacteria of the genus Akkermansia; and,- Allowing said bacteria of the genus Akkermansia to multiply.
- Method according to claim 1, wherein the bacteria of the genus Akkermansia are of the species Akkermansia muciniphila.
- Method according to claim 1 or 2, wherein the nitrogen-containing derivative of a monosaccharide is Glc-NAc.
- Method according to claim 1 to 3, wherein the Glc-NAc is present in an amount ranging from about 0.001 mM to about 1 M.
- Method according to any one of the preceding claims, wherein the glucose is present in an amount ranging from about 0.001 M to about 1 M.
- Method according to any one of the preceding claims, wherein the composition further comprises threonine.
- Method according to claim 6, wherein the threonine is present in an amount ranging from about 0.01 mM to about 100 mM.
- Method according to any one of the preceding claims, wherein the amino acid source is selected from a plant-based amino acid source, a microbial-based amino acid source, or a combination of alanine, glutamate, proline and serine.
- Method according to any one of the preceding claims, wherein the amino acid source is a plant protein hydrolysate.
- Method according to claim 9, wherein the plant protein hydrolysate is present in an amount ranging from about 0.01 g/l to about 1 kg/l, preferably from about 0.05 to about 500 g/l, more preferably about 0.1 to about 250 g/l.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20202373.5A EP3783010A1 (en) | 2015-05-06 | 2016-05-04 | Method of culturing akkermansia |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166598 | 2015-05-06 | ||
| PCT/EP2016/060039 WO2016177801A1 (en) | 2015-05-06 | 2016-05-04 | Method of culturing akkermansia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20202373.5A Division EP3783010A1 (en) | 2015-05-06 | 2016-05-04 | Method of culturing akkermansia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3292134A1 EP3292134A1 (en) | 2018-03-14 |
| EP3292134B1 true EP3292134B1 (en) | 2020-10-21 |
Family
ID=53059006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20202373.5A Pending EP3783010A1 (en) | 2015-05-06 | 2016-05-04 | Method of culturing akkermansia |
| EP16722128.2A Active EP3292134B1 (en) | 2015-05-06 | 2016-05-04 | Method of culturing akkermansia |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20202373.5A Pending EP3783010A1 (en) | 2015-05-06 | 2016-05-04 | Method of culturing akkermansia |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10988509B2 (en) |
| EP (2) | EP3783010A1 (en) |
| JP (2) | JP6925280B2 (en) |
| KR (2) | KR102615649B1 (en) |
| CN (1) | CN107849093B (en) |
| AU (1) | AU2016258976B2 (en) |
| CA (1) | CA2984986C (en) |
| DK (1) | DK3292134T3 (en) |
| EA (1) | EA201700497A1 (en) |
| IL (1) | IL255406B (en) |
| MX (1) | MX383750B (en) |
| PT (1) | PT3292135T (en) |
| WO (1) | WO2016177801A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| MX386592B (en) * | 2016-04-11 | 2025-03-19 | Univ Wageningen | NEW BACTERIAL SPECIES. |
| CN107384828B (en) * | 2017-08-22 | 2020-06-16 | 中国农业科学院农产品加工研究所 | Ackermann's myxobacteria culture medium and preparation method thereof |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| JP6993142B2 (en) * | 2017-08-31 | 2022-01-13 | 雪印メグミルク株式会社 | Composition for promoting Akkermansia muciniphila increase |
| JP6967404B2 (en) * | 2017-08-31 | 2021-11-17 | 雪印メグミルク株式会社 | Composition for promoting Akkermansia mucinifira increase |
| CN107903310B (en) * | 2017-11-16 | 2021-02-05 | 广州佰斯伦生物技术有限公司 | Recombinant membrane protein, microorganism, composition containing recombinant membrane protein and microorganism and application of composition |
| JP7811843B2 (en) | 2018-07-19 | 2026-02-06 | ペンデュラム セラピューティクス, インコーポレイテッド | Methods and compositions for microbial engraftment |
| KR102197180B1 (en) | 2018-10-11 | 2020-12-31 | 주식회사 고바이오랩 | Akkermansia muciniphila and composition for controlling appetite or preventing, improving, relieving and treating metabolic disease comprising the same |
| CN109355349B (en) * | 2018-11-30 | 2021-03-26 | 江南大学 | Ackermansoni specificity screening culture medium and preparation method and application thereof |
| CN109810931A (en) * | 2019-04-03 | 2019-05-28 | 广州康泽医疗科技有限公司 | A kind of culture medium and its application method for cultivating thermophilic mucin Ackermam Salmonella |
| CN110079474B (en) * | 2019-04-12 | 2022-11-25 | 沈阳药科大学 | A method for high-density cultivation of Ekmansia muciniphila |
| TWI719549B (en) * | 2019-07-22 | 2021-02-21 | 大江生醫股份有限公司 | Prebiotic composition for promoting growth of akkermansia muciniphila |
| CN110960558A (en) * | 2019-12-25 | 2020-04-07 | 西南大学 | A kind of preparation method of Akk bacteria animal capsules related to metabolic diseases |
| CN111304133B (en) * | 2020-03-20 | 2023-01-13 | 苏州普瑞森生物科技有限公司 | Culture medium for culturing akkermansia muciniphila and use method and application thereof |
| CN111763653B (en) * | 2020-07-16 | 2023-02-10 | 君维安(武汉)生命科技有限公司 | Culture method of akkermansia muciniphila based on novel electron acceptor |
| KR102222953B1 (en) * | 2020-11-11 | 2021-03-04 | 주식회사 엔테로바이옴 | Media supplement for high yield industrial culture of fastidious anaerobes and culture media comprising the same |
| US11377633B2 (en) | 2020-11-11 | 2022-07-05 | Enterobiome Inc. | Medium supplement for high-yield industrial culture of fastidious anaerobes and medium composition containing the same |
| EP4209582A4 (en) * | 2021-11-18 | 2023-11-01 | Enterobiome Inc. | Culture medium composition for faecalibacterium prausnitzii strain |
| WO2023102091A2 (en) * | 2021-12-01 | 2023-06-08 | Federation Bio, Inc. | Microbial consortia |
| KR102643788B1 (en) * | 2021-12-08 | 2024-03-07 | (주)헬스바이옴 | Culture media for producing high yield of Akkermansia sp., culturing method and freeze drying method using it |
| CN114350571B (en) * | 2022-02-09 | 2024-04-19 | 广州知易生物科技有限公司 | Non-animal-derived culture medium and method for culturing Acremonium muciniphilum by using same |
| CN114540246A (en) * | 2022-03-17 | 2022-05-27 | 中国科学院亚热带农业生态研究所 | A kind of selective medium and separation and identification method of AKK bacteria |
| CN116970506A (en) * | 2022-04-22 | 2023-10-31 | 厦门大学 | A method for cultivating Akkermansia by regulating pH in stages |
| CN115287233A (en) * | 2022-08-10 | 2022-11-04 | 暨南大学附属第一医院(广州华侨医院) | A kind of compound culture medium of Akkermansia and its preparation powder and application |
| CN115851529A (en) * | 2022-12-02 | 2023-03-28 | 广东悦创生物科技有限公司 | Akkermansia muciniphila modified medium |
| CN115975885B (en) * | 2022-12-23 | 2024-07-16 | 中国农业大学 | Preparation of mucin-philin Acremonium culture medium by using fish processing byproducts as nitrogen source |
| CN117701423A (en) * | 2023-11-30 | 2024-03-15 | 北京量化健康科技有限公司 | Culture medium and method for culturing akkermansia muciniphila |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2844484B2 (en) * | 1990-02-22 | 1999-01-06 | 味の素株式会社 | Method for producing recombinant protein |
| EP1849860B1 (en) | 1997-05-28 | 2010-11-17 | Novartis Vaccines and Diagnostics S.r.l. | Process for preparing an immunogenic factor of Corynebacterium diphtheriae using a culture medium with yeast extract as aminoacid source and no protein complexes of animal origin |
| US6558926B1 (en) | 1999-07-16 | 2003-05-06 | Massachusetts Institute Of Technology | Method for production of tetanus toxin using media substantially free of animal products |
| US20040265948A1 (en) * | 2003-06-27 | 2004-12-30 | White Michael Jon | Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters |
| US20050163764A1 (en) * | 2003-09-22 | 2005-07-28 | Yale University | Treatment with agonists of toll-like receptors |
| US7148041B2 (en) * | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
| JP2006238706A (en) * | 2005-02-28 | 2006-09-14 | Kanehide Bio Kk | Culturing medium of lactobacillus bifidus, method for culturing lactobacillus bifidus by using the same and food added with lactobacillus bifidus cultured by the method |
| KR102000371B1 (en) | 2012-11-14 | 2019-07-15 | 다이킨 고교 가부시키가이샤 | Method for producing dry etching gas |
| WO2014075745A1 (en) | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| PL2919796T3 (en) * | 2012-11-19 | 2021-09-27 | Université Catholique de Louvain | APPLICATION OF ACKERMANCY BACTERIA IN TREATMENT OF METABOLIC DISORDERS |
-
2016
- 2016-05-04 PT PT167243211T patent/PT3292135T/en unknown
- 2016-05-04 US US15/572,126 patent/US10988509B2/en active Active
- 2016-05-04 KR KR1020177034749A patent/KR102615649B1/en active Active
- 2016-05-04 EP EP20202373.5A patent/EP3783010A1/en active Pending
- 2016-05-04 AU AU2016258976A patent/AU2016258976B2/en active Active
- 2016-05-04 CA CA2984986A patent/CA2984986C/en active Active
- 2016-05-04 KR KR1020237043315A patent/KR20240001261A/en active Pending
- 2016-05-04 MX MX2017014089A patent/MX383750B/en unknown
- 2016-05-04 DK DK16722128.2T patent/DK3292134T3/en active
- 2016-05-04 CN CN201680026054.2A patent/CN107849093B/en active Active
- 2016-05-04 EA EA201700497A patent/EA201700497A1/en unknown
- 2016-05-04 JP JP2017557463A patent/JP6925280B2/en active Active
- 2016-05-04 EP EP16722128.2A patent/EP3292134B1/en active Active
- 2016-05-04 WO PCT/EP2016/060039 patent/WO2016177801A1/en not_active Ceased
-
2017
- 2017-11-02 IL IL255406A patent/IL255406B/en unknown
-
2021
- 2021-03-05 US US17/193,562 patent/US20210188923A1/en not_active Abandoned
- 2021-03-23 JP JP2021049097A patent/JP2021100425A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| None * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017023756A2 (en) | 2018-07-31 |
| US20210188923A1 (en) | 2021-06-24 |
| NZ737759A (en) | 2024-12-20 |
| EA201700497A1 (en) | 2018-05-31 |
| IL255406A0 (en) | 2017-12-31 |
| CN107849093B (en) | 2022-02-18 |
| EP3292134A1 (en) | 2018-03-14 |
| MX2017014089A (en) | 2018-08-15 |
| EP3783010A1 (en) | 2021-02-24 |
| IL255406B (en) | 2021-09-30 |
| CA2984986A1 (en) | 2016-11-10 |
| KR20240001261A (en) | 2024-01-03 |
| WO2016177801A1 (en) | 2016-11-10 |
| KR20180018524A (en) | 2018-02-21 |
| MX383750B (en) | 2025-03-14 |
| CA2984986C (en) | 2023-05-23 |
| AU2016258976A1 (en) | 2017-11-23 |
| DK3292134T3 (en) | 2020-11-23 |
| US10988509B2 (en) | 2021-04-27 |
| HK1252413A1 (en) | 2019-05-24 |
| AU2016258976B2 (en) | 2021-02-25 |
| JP2021100425A (en) | 2021-07-08 |
| KR102615649B1 (en) | 2023-12-19 |
| US20180094233A1 (en) | 2018-04-05 |
| JP2018515090A (en) | 2018-06-14 |
| CN107849093A (en) | 2018-03-27 |
| PT3292135T (en) | 2022-11-15 |
| JP6925280B2 (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10988509B2 (en) | Method of culturing Akkermansia | |
| US20210395677A1 (en) | Microorganism-Derived Protein Hydrolysates and Methods of Preparation and Use Thereof | |
| Tran et al. | Isolation and characteristics of Bacillus subtilis CN2 and its collagenase production | |
| Zhang et al. | Chemically defined media for commercial fermentations | |
| KR20160130950A (en) | A manufacturing methods of fermented soybean meal using lactic acid bacteria | |
| CN114787335B (en) | Medium supplement for high-yield cultivation of difficult-to-cultivate anaerobic microorganisms and medium composition containing the same | |
| KR100683948B1 (en) | Medium composition containing kochujang fermented product, brewed soy sauce stock solution or acid-decomposed soy sauce stock solution and method for producing gamma-aminobutyric acid | |
| Xiao et al. | High-yield production and characterization of α-galactosidase from Bifidobacterium breve grown on raffinose | |
| KR20240024958A (en) | Extracts derived from fast-growing microorganisms | |
| CN116965482B (en) | Method for preparing soybean enzymolysis protein by biological fermentation and application thereof | |
| HK1252413B (en) | Method of culturing akkermansia | |
| KR20180119979A (en) | A strain having high gamma-glutamyltransferase activity for flavor and taste, and method for manufacturing food composition using the same | |
| EA040261B1 (en) | METHOD FOR CULTIVATION OF AKKERMANSIA MUNICIPHILA BACTERIA | |
| EP0899326B1 (en) | Inactivated micro-organisms containing digestive enzymes, process for their preparation, and their use in the food sector | |
| BR112017023756B1 (en) | METHOD OF CULTIVATING AKKERMANSIA | |
| Ezemba et al. | Utilization of Various Starch Hydrolysates and Defatted Proteins by Bacillus cereus for Microbial Synthesis of Methionine in Submerged Medium | |
| KR100591493B1 (en) | Bacillus or yeast culture with increased glutaminase activity, preparation method thereof and preparation method of hydrolyzed protein using same | |
| RU2207019C1 (en) | Biologically active food additive and a method of preparation thereof | |
| KR102734764B1 (en) | Bacillus amyloliquefaciens MU2 strain and Chlorella protein extraction method using the same | |
| KR20150004088A (en) | A manufacturing methods of fermented soybean meal using lactic acid bacteria | |
| KR100694427B1 (en) | Microorganisms of Corynebacterium and Preparation Method of 5'-inosinic Acid Using the Same | |
| JPH07265066A (en) | Peptone for culture medium for culturing microorganism | |
| JPS6391076A (en) | Cultivation of three kinds of bacteria | |
| EP2275527A1 (en) | Animal component-free culture medium for bacterial fermentation | |
| KR20170018222A (en) | Composition comprising microoraganism having protease activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20171206 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20190212 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1252413 Country of ref document: HK |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602016046207 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07K0014195000 Ipc: A61K0038000000 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/195 20060101ALI20200415BHEP Ipc: A61P 3/08 20060101ALI20200415BHEP Ipc: A61P 3/06 20060101ALI20200415BHEP Ipc: A61K 38/00 20060101AFI20200415BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20200513 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016046207 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1325155 Country of ref document: AT Kind code of ref document: T Effective date: 20201115 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20201117 |
|
| REG | Reference to a national code |
Ref country code: FI Ref legal event code: FGE |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1325155 Country of ref document: AT Kind code of ref document: T Effective date: 20201021 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210121 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210222 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210122 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210221 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016046207 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20210722 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210504 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210504 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210221 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160504 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201021 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20250523 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20250520 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20250519 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20250522 Year of fee payment: 10 Ref country code: DK Payment date: 20250521 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20250530 Year of fee payment: 10 Ref country code: BE Payment date: 20250520 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20250521 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BG Payment date: 20250516 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20250601 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20250522 Year of fee payment: 10 |